Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- MTI University
- Target Recruit Count
- 60
- Registration Number
- NCT05429554
- Locations
- 🇪🇬
National Institute of diabetes and endocrinology, Cairo, Al Kasr Al Aini, Egypt
Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 567
- Registration Number
- NCT05366868
- Locations
- 🇯🇵
Center Hospital of the National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan
Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Getz Pharma
- Target Recruit Count
- 120
- Registration Number
- NCT05359432
- Locations
- 🇵🇰
Department of Diabetes and Endocrinology at Sindh Government Hospital New Karachi & Dr. Riasat Medical Center Allah Wala Town, Karachi, Pakistan, Karachi, Sindh, Pakistan
Cognitive Protective Effect of Newer Antidiabetic Drugs
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT05347459
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 672
- Registration Number
- NCT05102149
- Locations
- 🇨🇳
Shiyan Renmin Hospital, Shiyan, Hubei, China
🇨🇳Lu'an People's Hospital, Lu'an, Anhui, China
🇨🇳Lanzhou University Second Hospital, Lanzhou, Gansu, China
DPP4 Inhibitor on Glycemic Variability
- Conditions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- University Malaysia Sarawak
- Target Recruit Count
- 12
- Registration Number
- NCT04654676
- Locations
- 🇲🇾
Sarawak General Hospital, Kuching, Malaysia
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 39
- Registration Number
- NCT04485845
- Locations
- 🇪🇬
National Diabetes & Endocrinology Institute, Cairo, Egypt
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 69
- Registration Number
- NCT04300790
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸Hospital Universitario de Leon, León, Spain
🇪🇸Hospital Beata María Ana, Madrid, Spain
Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 120
- Registration Number
- NCT03925701
- Locations
- 🇪🇬
Tanta University, Tanta, Egypt
Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- Chiang Mai University
- Target Recruit Count
- 43
- Registration Number
- NCT03178591
- Locations
- 🇹🇭
Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.